Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia

Pediatrics

Volumn 121, Issue 6, 2008, Pages 1253-1256

  Vichinsky, Elliott ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON; IRON CHELATING AGENT; ORPHAN DRUG; TRANSFERRIN; CHELATING AGENT;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANEMIA; ARTHRALGIA; BLOOD TRANSFUSION; CHILD; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOPENIA; DEVELOPMENTAL DISORDER; DIARRHEA; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; GROWTH RATE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LIVER INJURY; NAUSEA; NEUTROPENIA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RARE DISEASE; RASH; SEXUAL MATURATION; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SIDE EFFECT; THALASSEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; ADOLESCENT; ARTICLE; CHRONIC DISEASE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ANEMIA; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; ERYTHROCYTE TRANSFUSION; HUMANS; IRON; IRON OVERLOAD;

EID: 48949084181     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-1824     Document Type: Note

References (53)

1. Weatherall D, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-712
2. Sickle Cell Disease Guideline Panel. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants- Clinical Practice Guideline Number 6. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; 1993. Publication 93-0562
3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023
4. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol. 2001;38(1 suppl 1):5-13
5. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769- 2778
6. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896-899
7. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352
8. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252
9. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201
10. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood. 2004;104(1):34-39
11. De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Biochem. 2006;19(4):471-480
12. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-331
13. Jensen PD. Evaluation of iron overload. Br J Haematol. 2004; 124(6):697-711
14. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22(23):2171-2179
15. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta- thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121(6):938-948
16. Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329-332
17. Fischer R, Piga A, Harmatz P, Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci. 2005;1054:350-357
18. Piga A, Fischer R, Harmatz T, et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with deferasirox (Exjade®, ICL670) [abstract]. Blood. 2005;106(11):2689
19. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9): 567-573
20. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054: 40-47
21. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-1193
22. Davis BA, Porter JB. Long-term outcome of continuous 24hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood. 2000;95(4):1229-1236
23. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36
24. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42(2 suppl 1):S19 -S21
25. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-1587
26. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918 -922
27. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferipronetreated patients with thalassemia major. Blood. 2006;107(9): 3733-3737
28. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516 -520
29. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744
30. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with trans- fusional iron overload. Ann Hematol. 2006;85(5):315-319
31. Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci. 2005;1054:175-182
32. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006;36(1):21-25
33. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebocontrolled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884
34. Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007: July 18(3):CD004839
35. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003; 102(1):17-24
36. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol. 2005; 74(3):217-220
37. Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007; 109(12):5157-5159
38. Olivieri NF, Brittenham GM. Long-term trials of deferiprone in Cooley's anemia. Ann N Y Acad Sci. 1998;850:217-222
39. Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]. Blood. 2005;106(11):2704
40. Cappellini MD, Cohen A, Piga A et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455-3462
41. Galanello R, Piga A, Forni G-L, etal. Phase IIclinicalevaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica. 2006; 91(10):1343-1351.
42. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508
43. Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade®), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload [abstract]. Blood. 2004;104(11):3193
44. Piga A, Bejaoui M, Kilinc Y, et al. Long-term treatment with the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is effective and generally well tolerated in pediatric patients [abstract]. Blood. 2006;108:506a
45. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol. 2007; In Press
46. Porter J. Clinical evaluation of deferasirox (ExjadeICL670). Semin Hematol. 2007;44(2 suppl 3):S16-S20
47. Daar S, Taher A, Pathare A, Nick H, Krahn U, Hadler D. Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade, ICL670) in iron-overloaded β-thalassemia patients [abstract]. Blood. 2006;
48. 108:503a
49. Wood JC, Otto-Duessel M, Gonzales I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl R.es. 2006;148(5):272-280
50. Eleftheriou P, Tanner M, Pennell D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [abstract]. Haematologica. 2006;91(suppl 1):999
51. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox) [abstract]. Blood. 2005;106(11):1003a
52. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739 -761
53. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of Deferasirox (Exjade,ICL670) versus Deferox- amine in sickle cell disease patients with transfusional hemo- siderosis. Acta Haematol. 2008; In Press